Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0

Imatinib targeting of KIT-mutant oncoprotein in melanoma


ABSTRACT: Metastatic melanoma is an aggressive treatment-refractory malignancy. Recently, c-Kit mutations were discovered in certain mucosal melanomas. A clinical trial was initiated with the c-Kit inhibitor imatinib mesylate. The first treated patient experienced dramatic clinical improvement within days, followed by major responses by PET/CT four weeks later at all sites of metastatic disease. Several established mucosal melanoma cell lines exhibited imatinib sensitivity in a fashion correlating with c-Kit mutational status. Although c-Kit mutations are uncommon in cutaneous melanoma, they may arise in geographically distinct subsets for whom use of c-Kit targeted kinase inhibition should be considered in a rational therapeutic approach. Keywords: Whole genome copy number analysis Copy number analysis using high-density SNP arrays to investigate genetic gains and losses involved in the genesis of mucosal and cutaneous melanoma. GSE8164_raw_copy_number_calls.xls contains raw copy number calls generated by dChip (build 5/2007) for GIST, K008, K029, M34, MEL1, MEL40, M6, and 5 Affymetrix controls (copy number identity 2 i.e. normal), which are available on the HapMAP site.

ORGANISM(S): Homo sapiens

SUBMITTER: Stephen Hodi 

PROVIDER: E-GEOD-8164 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

altmetric image

Publications

Imatinib targeting of KIT-mutant oncoprotein in melanoma.

Jiang Xiaofeng X   Zhou Jun J   Yuen Noah K NK   Corless Christopher L CL   Heinrich Michael C MC   Fletcher Jonathan A JA   Demetri George D GD   Widlund Hans R HR   Fisher David E DE   Hodi F Stephen FS  

Clinical cancer research : an official journal of the American Association for Cancer Research 20081201 23


<h4>Purpose</h4>Melanoma subtypes based on anatomic location and UV light exposure can be further classified based on genetic alterations recently identified. Mutations and gene amplification in KIT have been described in a significant percentage of mucosal and acral melanomas. We recently reported a patient with metastatic mucosal melanoma harboring a known KIT mutation treated with imatinib mesylate who experienced a major response. Biological effects of KIT inhibition in these melanomas remai  ...[more]

Similar Datasets

2016-11-24 | E-MTAB-5265 | biostudies-arrayexpress
2010-12-16 | E-GEOD-24412 | biostudies-arrayexpress
2014-07-01 | E-GEOD-56298 | biostudies-arrayexpress
2016-06-01 | E-GEOD-79095 | biostudies-arrayexpress
2013-02-14 | E-GEOD-44092 | biostudies-arrayexpress
2013-05-30 | E-GEOD-47453 | biostudies-arrayexpress
2013-08-29 | E-GEOD-50218 | biostudies-arrayexpress
2013-12-31 | E-GEOD-45911 | biostudies-arrayexpress
2015-07-30 | E-GEOD-59945 | biostudies-arrayexpress
2016-08-09 | E-GEOD-79314 | biostudies-arrayexpress